Options
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision
ISSN
1814-1412
1562-2975
Date Issued
2008
Author(s)
Zohar, Joseph
Hollander, Eric
Kasper, Siegfried
Moeller, Hans-Juergen
Allgulander, Christer
Ayuso-Gutierrez, Jose
Baldwin, David S.
Bunevicius, Robertas
Cassano, Giovanni
Fineberg, Naomi A.
Gabriels, Loes
Hindmarch, Ian
Kaiya, Hisanobu
Klein, Donald F.
Lader, Malcolm
Lecrubier, Yves
Lepine, Jean-Pierre
Liebowitz, Michael R.
Lopez-Ibor, Juan Jose
Marazziti, Donatella
Miguel, Euripedes C.
Oh, Kang Seob
Preter, Maurice
Rupprecht, Rainer
Sato, Mitsumoto
Starcevic, Vladan
Stein, Dan J.
van Ameringen, Michael
Vega, Johann
DOI
10.1080/15622970802465807
Abstract
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.